Compare · ALZN vs PRTA
ALZN vs PRTA
Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALZN and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PRTA is the larger of the two at $419.0M, about 70.0x ALZN ($6.0M).
- PRTA has been more active in the news (10 items in the past 4 weeks vs 1 for ALZN).
- PRTA has more recent analyst coverage (22 ratings vs 1 for ALZN).
- Company
- Alzamend Neuro Inc.
- Prothena Corporation plc
- Price
- -
- -
- Market cap
- $6.0M
- $419.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 10
- Recent ratings
- 1
- 22
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest ALZN
- Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Alzamend Neuro Inc.
- SEC Form S-1 filed by Alzamend Neuro Inc.
Latest PRTA
- SEC Form 3 filed by new insider Fennell Todd W.
- Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc
- Large owner Scully William P gifted 916,444 units of Ordinary Shares and bought $1,194,158 worth of Ordinary Shares (140,000 units at $8.53), decreasing direct ownership by 44% to 977,000 units (SEC Form 4)
- SEC Form 10-Q filed by Prothena Corporation plc
- Prothena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
- SEC Form 8-K filed by Prothena Corporation plc
- Prothena to Report Third Quarter 2026 Financial Results on November 5
- SEC Form 4 filed by Prothena Corporation plc
- Large owner Scully William P bought $1,222,045 worth of Ordinary Shares, par value $0.01 per share (150,000 units at $8.15) (SEC Form 4)